Celsion and Yakult have executed a letter of intent relating to the commercialization of ThermoDox for the Japanese markets, which is subject to the execution of definitive agreements.
Michael Tardugno, president and CEO of Celsion, said: “We are delighted to be able to announce our arrangement with Yakult, one of Japan’s leading nutritionals and healthcare corporations. Their interest in working with Celsion to develop ThermoDox’s potential to treat primary liver cancer further confirms our confidence in the promise that we’ve seen in our early phase studies and adds significant bench strength to our clinical program.”